Aging delays resolution of acute inflammation in mice: Reprogramming the host response with novel nano-proresolving medicines

Journal of Immunology

Volumn 193, Issue 8, 2014, Pages 4235-4244

  Arnardottir, Hildur H ^a   Dalli, Jesmond ^a   Colas, Romain A ^a   Shinohara, Masakazu ^a   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AUTACOID; DOCOSAHEXAENOIC ACID; RESOLVIN D1; RESOLVIN D3; SPECIALIZED PRORESOLVING LIPID MEDIATOR; UNCLASSIFIED DRUG; ICOSAPENTAENOIC ACID; UNSATURATED FATTY ACID; ZYMOSAN;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MACROPHAGE; MALE; MASS SPECTROMETRY; MONOCYTE; MOUSE; NONHUMAN; PERITONITIS; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; METABOLOMICS; MONONUCLEAR CELL; NANOMEDICINE; PRINCIPAL COMPONENT ANALYSIS;

AGING; ANIMALS; ASPIRIN; AUTACOIDS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MALE; METABOLOMICS; MICE; MICE, INBRED BALB C; NANOMEDICINE; PERITONITIS; PRINCIPAL COMPONENT ANALYSIS; ZYMOSAN;

EID: 84907487380     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401313     Document Type: Article

References (35)

1. Majno, G., and I. Joris. 2004. Cells, Tissues, and Disease: Principles of General Pathology. Oxford University Press, New York.
2. Serhan, C. N., and N. Chiang. 2013. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr. Opin. Pharmacol. 13: 632-640.
3. Tabas, I., and C. K. Glass. 2013. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339: 166-172.
4. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R.-L. Moussignac. 2002. Resolvins: a family of bioactive products of v-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037.
5. Gordon, S., and A. Pluddemann. 2013. Tissue macrophage heterogeneity: issues and prospects. Semin. Immunopathol. 35: 533-540.
6. Sica, A., and A. Mantovani. 2012. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122: 787-795.
7. Fullerton, J. N., A. J. O'Brien, and D. W. Gilroy. 2013. Pathways mediating resolution of inflammation: when enough is too much. J. Pathol. 231: 8-20.
8. Shaw, A. C., D. R. Goldstein, and R. R. Montgomery. 2013. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13: 875-887.
9. Sampaio, A. L. F., N. Dufton, and M. Perretti. 2010. Models of acute inflammation- air pouch, peritonitis, and ischemia-reperfusion. In Fundamentals of Inflammation. C. N. Serhan, P. A. Ward, and D. W. Gilroy, eds. Cambridge University Press, New York, p. 329-337.
10. Norling, L. V., M. Spite, R. Yang, R. J. Flower, M. Perretti, and C. N. Serhan. 2011. Cutting edge: humanized nano-proresolving medicines mimic inflammationresolution and enhance wound healing. J. Immunol. 186: 5543-5547.
11. Janes, K. A., and M. B. Yaffe. 2006. Data-driven modelling of signaltransduction networks. Nat. Rev. Mol. Cell Biol. 7: 820-828.
12. Dalli, J., and C. N. Serhan. 2012. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and proresolving mediators. Blood 120: e60-e72.
13. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
14. Doherty, N. S., P. Poubelle, P. Borgeat, T. H. Beaver, G. L. Westrich, and N. L. Schrader. 1985. Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E2. Prostaglandins 30: 769-789.
15. Titos, E., B. Rius, A. González-Périz, C. López-Vicario, E. Morán-Salvador, M. Martínez-Clemente, V. Arroyo, and J. Clària. 2011. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 187: 5408-5418.
16. Stables, M. J., S. Shah, E. B. Camon, R. C. Lovering, J. Newson, J. Bystrom, S. Farrow, and D. W. Gilroy. 2011. Transcriptomic analyses of murine resolution-phase macrophages. Blood 118: e192-e208.
17. Jones, C. N., J. Dalli, L. Dimisko, E. Wong, C. N. Serhan, and D. Irimia. 2012. Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc. Natl. Acad. Sci. USA 109: 20560-20565.
18. Zhang, G., J. Li, S. Purkayastha, Y. Tang, H. Zhang, Y. Yin, B. Li, G. Liu, and D. Cai. 2013. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature 497: 211-216.
19. Xu, M. X., B. C. Tan, W. Zhou, T. Wei, W. H. Lai, J. W. Tan, and J. H. Dong. 2013. Resolvin D1, an endogenous lipid mediator for inactivation of inflammation-related signaling pathways in microglial cells, prevents lipopolysaccharide-induced inflammatory responses. CNS Neurosci. Ther. 19: 235-243.
20. Schauer, C., C. Janko, L. E. Munoz, Y. Zhao, D. Kienhöfer, B. Frey, M. Lell, B. Manger, J. Rech, E. Naschberger, et al. 2014. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat. Med. 20: 511-517.
21. Ariel, A., G. Fredman, Y.-P. Sun, A. Kantarci, T. E. Van Dyke, A. D. Luster, and C. N. Serhan. 2006. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 7: 1209-1216.
22. Chiang, N., G. Fredman, F. Bäckhed, S. F. Oh, T. Vickery, B. A. Schmidt, and C. N. Serhan. 2012. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484: 524-528.
23. Morita, M., K. Kuba, A. Ichikawa, M. Nakayama, J. Katahira, R. Iwamoto, T. Watanebe, S. Sakabe, T. Daidoji, S. Nakamura, et al. 2013. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell 153: 112-125.
24. Gangemi, S., L. Pescara, E. D'Urbano, G. Basile, V. Nicita-Mauro, G. Davì, and M. Romano. 2005. Aging is characterized by a profound reduction in antiinflammatory lipoxin A4 levels. Exp. Gerontol. 40: 612-614.
25. Dakin, S. G., J. Dudhia, N. J. Werling, D. Werling, D. R. Abayasekara, and R. K. Smith. 2012. Inflamm-aging and arachadonic acid metabolite differences with stage of tendon disease. PLoS ONE 7: e48978.
26. Schif-Zuck, S., N. Gross, S. Assi, R. Rostoker, C. N. Serhan, and A. Ariel. 2011. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41: 366-379.
27. Hellmann, J., Y. Tang, M. Kosuri, A. Bhatnagar, and M. Spite. 2011. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J. 25: 2399-2407.
28. Dalli, J., M. Zhu, N. A. Vlasenko, B. Deng, J. Z. Haeggström, N. A. Petasis, and C. N. Serhan. 2013. The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J. 27: 2573-2583.
29. Nassar, G. M., J. D. Morrow, L. J. Roberts, II, F. G. Lakkis, and K. F. Badr. 1994. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 269: 27631-27634.
30. De Caterina, R. 2011. n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364: 2439-2450.
31. Calder, P. C. 2013. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br. J. Clin. Pharmacol. 75: 645-662.
32. Pomponi, M. F., G. Gambassi, M. Pomponi, and C. Masullo. 2010. Alzheimer's disease: fatty acids we eat may be linked to a specific protection via low-dose aspirin. Aging Dis. 1: 37-59.
33. Lima-Garcia, J. F., R. C. Dutra, K. da Silva, E. M. Motta, M. M. Campos, and J. B. Calixto. 2011. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol. 164: 278-293.
34. Giera, M., A. Ioan-Facsinay, R. Toes, F. Gao, J. Dalli, A. M. Deelder, C. N. Serhan, and O. A. Mayboroda. 2012. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim. Biophys. Acta 1821: 1415-1424.
35. Mas, E., K. D. Croft, P. Zahra, A. Barden, and T. A. Mori. 2012. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58: 1476-1484.